Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era

Updated data demonstrated that patients who had received ≥2 prior HER2-based regimens treated with Enhertu achieved an objective response rate of 61.4%, median duration of response of 20.8 months and median progression-free survival of 19.4 months.

Source:

Thorax